SaaS Software

IQ-UIP™

A New Approach to UIP Identification for IPF Management

FDA “Breakthrough Device”–Advancing EarlyDetection and Intervention

IQ-UIP™ is state-of-the-art software powered by deep learning, designed to accurately classify Usual Interstitial Pneumonia (UIP) and predict patient survival directly from inspiratory CT scans. Achieving expert-level performance, IQ-UIP matches the accuracy of seasoned CT readers and was FDA-cleared in 2024, establishing a new standard for pulmonary diagnostics.

FDA 510(k) Cleared, For Investigational Use Only outside of the United States

The Challenge: Timely, Accurate UIP Diagnosis

  • Delayed Diagnosis: UIP, most frequently associated with idiopathic pulmonary fibrosis (IPF), is notoriously difficult to diagnose. On average, patients consult three or more physicians, undergo multiple CT scans 1,and wait up to two years for a definitive diagnosis losing precious time for treatment.

  • Poor Prognosis: After diagnosis, expected survival is only 3–5 years2, further reduced by diagnostic delays.Early, accurate detection is essential to meaning fully extend patients’ live
  • Diagnostic Overlap:  UIP symptoms are often mistaken forother lung diseases such as COPD or asthma—contributing to a misdiagnosis rate exceeding 50%.3

The IQ-UIP Solution: Powerful, AI Proactive Care

Expert-Level Performance

Achieves 90.2% sensitivity and 91.5% specificity in UIP detection, comparable to the results of thoracic radiologist panels.4

Scalable Access

Consistent, accurate screening is available across all healthcare environments, including those with limited access to sub specialists. 

For Your Practice

IQ-UIP

IQ-UIP redefines pulmonary diagnostics—supporting earlier,more confident UIPidentification and connecting patientswith the expert care they need when every moment matters.

  • Faster, More Accurate Identification:  Immediately highlights UIP patterns—including subpleural fibrosis and honeycombing—for actionable results directly from standard inspiratory CT scans.

Suggested use cases for IQ-UIP

  • Population Health Screening: Incidental IQ-UIP detection on all eligible chest CTs across health systems

1 Hoyer, N., Prior, T.S., Bendstrup, E. et al. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res 20,103 (2019).https://doi.org/10.1186/s12931-019-1076-0
2 Khor YH, NgY, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev. 2020 Aug 4;29(157):190158. doi: 10.1183/16000617.0158-2019. PMID: 32759374; PMCID:PMC9488716.
3 Cosgrove, G.P., Bianchi, P., Danese, S. et al. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med 18, 9 (2018).https://doi.org/10.1186/s12890-017-0560-x
4 Data on file

Imbio, a fully owned subsidiary of 4DMedical, is the legal manufacturer of IQ-UIP

 

What's new at 4DMedical

Get the latest news about respiratory imaging and ventilation analysis